The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Universitą della Svizzera italiana), has received a 4-year grant of 700.000 CHF from the Swiss National Science Foundation (SNSF) to investigate a transcription factor (ETS) that acts as tumor suppressor to prevent development of aggressive prostate tumors in men, which is the most common cancer and one of leading causes of cancer related death.
The project ("The ETS transcription factor ESE3/EHF as a regulator of prostate epithelial cell differentiation and stem cell properties"), is expected to provide important new insights with a high potential to impact on clinical management of prostate cancer patients. Thanks to this grant, Dr. Carbone and her team will continue their research efforts towards a more comprehensive understanding of the role of this regulatory protein in blocking the development of tumors by employing multiple approaches and experimental models.
Dr. Carbone has a longstanding record of accomplishments in investigating the role of ETS transcription factors in prostate cancer. ETS transcription factors are regulatory proteins that control several cellular functions in many tissues.
In past years, Dr. Carbone has achieved significant breakthroughs in identifying and demonstrating the tumor suppressive function of the ETS factor ESE3/EHF in prostate cancer.
For further details on the work of Dr. Carbone and her research group : ior.iosi.ch/site/?facstaff=giuseppina-carbone-md